ABO-incompatible kidney transplantation: current practice and the decade ahead

Purpose of reviewWith rapidly growing deceased donor kidney transplant waiting lists, solutions to the shortage of kidney donors need to come from many corners. This review focuses on the current results and upcoming medications that will allow broad expansion of ABO-incompatible transplantation as one facet to combat this issue. Recent findingsOutcomes of ABO-incompatible kidney transplantation are comparable to standard living donor transplantation but carry a significant, early risk of antibody-mediated rejection. Reducing this early rejection risk will be critical for a broader adaption of incompatible transplants. Improvements in the measurement of isohemagglutinin antibodies with less variability, will reduce patient risk. The anti-CD20 antibody rituximab has replaced splenectomy at most centers with equivalent outcomes, eliminating the need for additional surgical intervention. Studies of complement inhibitors have proven effective in treating antibody-mediated rejection in animal models and human studies are currently ongoing. Studies in xenotransplantation show that blood group carbohydrate antigens can be effectively removed ex vivo prior to implantation. Ongoing studies of accomodation in animal models are finding protective changes in endothelial cells and the immune system that could become targets for pharmacologic manipulation. SummaryImprovements that reduce risk of early rejection and its long-term sequelae will allow ABO-incompatible kidney transplantation to be adopted broadly along with paired kidney exchange programs, to address the donor organ shortage.

[1]  T. Shimizu,et al.  Acute Antibody‐Mediated Rejection in Living ABO‐Incompatible Kidney Transplantation: Long‐Term Impact and Risk Factors , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  C. Legendre,et al.  Antibody‐Mediated Microcirculation Injury Is the Major Cause of Late Kidney Transplant Failure , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  H. Shirakawa,et al.  Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. , 2009, Contributions to nephrology.

[4]  G. Tydén,et al.  Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. , 2007, Transplantation.

[5]  Kota Takahashi,et al.  Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation , 2007, Clinical and Experimental Nephrology.

[6]  Lloyd E Ratner,et al.  The Altruistic Unbalanced Paired Kidney Exchange: Proof of Concept and Survey of Potential Donor and Recipient Attitudes , 2010, Transplantation.

[7]  T. Fehr,et al.  Late Steroid Withdrawal After ABO Blood Group-Incompatible Living Donor Kidney Transplantation: High Rate of Mild Cellular Rejection , 2010, Transplantation.

[8]  Akimasa Nakao,et al.  Removal of blood group A/B antigen in organs by ex vivo and in vivo administration of endo-beta-galactosidase (ABase) for ABO-incompatible transplantation. , 2009, Transplant immunology.

[9]  S. Kawachi,et al.  Neutralization of Blood Group A-Antigen by a Novel Anti-A Antibody: Overcoming ABO-Incompatible Solid-Organ Transplantation , 2008, Transplantation.

[10]  T. Fehr,et al.  Changes of Circulating Antibody Levels Induced by ABO Antibody Adsorption for ABO‐Incompatible Kidney Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  Y. Yamaguchi,et al.  Impact of low‐dose rituximab on splenic B cells in ABO‐incompatible renal transplant recipients , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  R. Montgomery,et al.  Therapeutic plasma exchange reduces ABO titers to permit ABO‐incompatible renal transplantation , 2009, Transfusion.

[13]  K. Tanabe.  Japanese Experience of ABO-Incompatible Living Kidney Transplantation , 2007, Transplantation.

[14]  D. Segev,et al.  The Use of Antibody to Complement Protein C5 for Salvage Treatment of Severe Antibody‐Mediated Rejection , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  M. Stegall,et al.  The Effect of Desensitization Protocols on Human Splenic B‐Cell Populations In Vivo , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  R. Blagojević,et al.  Simple "closed-circuit" group-specific immunoadsorption system for ABO-incompatible kidney transplants. , 2007, Transfusion and Apheresis Science.

[17]  R. Higgins,et al.  Application of flow cytometry to monitor antibody levels in ABO incompatible kidney transplantation. , 2008, Transplantation.

[18]  A. Kribben,et al.  Eculizumab for atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.

[19]  U. Berg,et al.  ABO-Incompatible Kidney Transplantation Using Antigen-Specific Immunoadsorption and Rituximab: A 3-Year Follow-up , 2008, Transplantation.

[20]  J. Squifflet,et al.  Present experiences in a series of 26 ABO-incompatible living donor renal allografts. , 1987, Transplantation proceedings.

[21]  N. Marcussen,et al.  Acute antibody-mediated rejection after ABO-incompatible kidney transplantation treated successfully with antigen-specific immunoadsorption. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  Takaaki Kobayashi,et al.  A series of surveys on assay for anti‐A/B antibody by Japanese ABO‐incompatible Transplantation Committee , 2006, Xenotransplantation.

[23]  P. Gianello,et al.  Accommodation and antibodies. , 2009, Transplant immunology.

[24]  M. Stegall,et al.  Histologic Findings One Year After Positive Crossmatch or ABO Blood Group Incompatible Living Donor Kidney Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  G. Tydén,et al.  Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies , 2006, Transfusion.

[26]  D. Segev,et al.  ABO Incompatible High‐Titer Renal Transplantation without Splenectomy or Anti‐CD20 Treatment , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  T. Shimizu,et al.  Evaluation of Immunosuppressive Regimens in ABO‐Incompatible Living Kidney Transplantation—Single Center Analysis , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.